Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.18538 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Milia En Plaque After Bullous Pemphigoid: An Unusual Sequela.
Cureus
November 2024
Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA.
We present the case of a 36-year-old paraplegic woman with a history of spinal cord injury who developed a generalized blistering rash, later diagnosed as bullous pemphigoid (BP). During her hospitalization, she was treated with prednisone and rituximab infusions, transitioning to maintenance therapy with topical steroids, doxycycline, and nicotinamide. A year later, she presented with concerns about a BP flare on her feet.
View Article and Find Full Text PDFUpdates on the Management of Autoimmune Bullous Diseases.
Indian Dermatol Online J
August 2024
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
Article Synopsis
- Autoimmune bullous diseases pose significant health risks, and traditional treatments like corticosteroids have serious side effects, leading to the need for targeted therapies.
- * This review focuses on newer therapeutic options for conditions like pemphigus and bullous pemphigoid, examining various emerging treatments and their effectiveness.
- * The conclusion emphasizes the importance of ongoing research to identify the best and safest treatment strategies for individuals affected by these diseases.
Radiotherapy-induced pemphigus foliaceus successfully treated with rituximab.
Int J Dermatol
August 2024
Department of Dermatology, Mater Dei Hospital, Msida, Malta.
Key Clinical Message: Rituximab-induced serum sickness (RISS) is a rare complication of Rituximab (RTX) in immunobullous disorders. Clinicians should be aware of the occurrence of serum sickness symptoms during RTX administration, and prompt initiation of corticosteroid therapy is crucial in these patients. Additionally, RISS may occur with subsequent RTX doses and patients should be counseled accordingly.
View Article and Find Full Text PDFRituximab in Pemphigus - An Observational Study from a Tertiary Care Center of North India.
Indian Dermatol Online J
September 2022
Department of Dermatology, Venereology and Leprosy, Government Medical College, Karan Nagar, Srinagar, Jammu and Kashmir, India.
Background: Pemphigus is a group of potentially fatal autoimmune mucocutaneous blistering diseases. Rituximab (RTX) is a chimeric anti-CD20 (anti-cluster of differentiate 20) monoclonal antibody being increasingly used and becoming the first-line therapy in the management of pemphigus.
Aims And Objectives: This was an observational study to evaluate the efficacy and safety of rituximab in patients of pemphigus vulgaris (PV) who either did not respond or relapsed after conventional therapeutic regimens and in treatment naive pemphigus patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!